GSDMD and dry eye syndrome: NLRP12/NLRC4 knockdown, GSDMD knockout, or the neutralization of mature IL-33 can obviously attenuate the damage to corneal epithelial cells, indicating that these molecules could be key targets for dry eye treatment in the future (Chen et al., 2020b).